A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. CPT-11 Lung Cancer Study Group.

A phase I trial of the combination of irinotecan (CPT-11) with cisplatin in advanced non-small cell lung cancer (NSCLC) showed a very promising response rate of 54% in previously untreated NSCLC patients. This study was conducted to confirm the activity and toxicities of CPT-11 and cisplatin combina...

Descripción completa

Detalles Bibliográficos
Autores principales: Masuda, N., Fukuoka, M., Fujita, A., Kurita, Y., Tsuchiya, S., Nagao, K., Negoro, S., Nishikawa, H., Katakami, N., Nakagawa, K., Niitani, H.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group|1 1998
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2062886/
https://www.ncbi.nlm.nih.gov/pubmed/9683302

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2062886/
https://www.ncbi.nlm.nih.gov/pubmed/9683302

Ejemplares similares